GHK-Cu (copper peptide, glycyl-L-histidyl-L-lysine-copper) has been in skincare products since the 1990s. It's in serums, creams, and injectable protocols. The research behind it is genuinely interesting — some of it substantially more interesting than most of what's in a cosmetic counter. It's also more limited, less consistent, and less applicable to the specific claims on the bottle than the marketing implies.

What GHK-Cu Is

GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, and urine. It was first isolated by Loren Pickart in 1973 while studying the rejuvenating effect of young plasma on older liver tissue. Pickart found that GHK specifically was responsible for the observed regenerative activity. It has a strong affinity for copper ions, forming the GHK-Cu complex that is the active form used in most research and commercial applications.

Serum GHK levels decline substantially with age — from roughly 200 ng/mL in young adults to under 80 ng/mL in people over 60. This age-related decline, combined with the compound's observed biological activity, is the foundation of the anti-aging narrative.

The Mechanisms (They're Real)

GHK-Cu's mechanisms are better characterized than most cosmetic peptides. Published research shows it:

  • Stimulates collagen synthesis — specifically type I, III, and IV collagen, as well as glycosaminoglycans (the structural matrix components that give skin its volume and elasticity)
  • Promotes angiogenesis via VEGF upregulation — relevant for wound healing, less clearly relevant for cosmetic application
  • Has anti-inflammatory activity, partly through modulating TNF-alpha and other inflammatory mediators
  • Activates antioxidant enzymes including superoxide dismutase and catalase
  • Has documented wound-healing activity in animal models and some controlled human wound-healing studies
  • Activates more than 4,000 genes in Pickart's gene expression work — a finding that is either remarkable or concerning depending on how you interpret broad transcriptional effects

This is a more solid mechanistic foundation than most peptides marketed for skin. The question is whether the mechanisms translate into the outcomes being claimed on product labels.

The Clinical Evidence (It's Thinner Than the Mechanism)

The human clinical data for GHK-Cu falls mostly into two categories: wound healing studies and cosmetic anti-aging trials.

The wound healing evidence is the strongest. Several controlled studies — mostly small, but real — show GHK-Cu accelerates healing in surgical wounds, burns, and chronic ulcers when applied topically. This is the application where mechanism-to-outcome translation is most direct: apply a wound-healing compound to a wound, observe whether it heals faster. Several studies show it does. This is legitimate evidence of a real effect.

The cosmetic anti-aging evidence is more complicated. Pickart's group published multiple studies showing GHK-Cu reduces wrinkle depth, increases skin density, and improves skin firmness in cosmetic trials. Independent validation of these results has been limited. Most published cosmetic trials of GHK-Cu are small (20-60 participants), not always placebo-controlled, of short duration (12 weeks being typical), and funded by entities with financial interest in positive results.

A 2005 comparative study found GHK-Cu performed comparably to retinol for several skin aging parameters — an interesting result, since retinol has much stronger clinical evidence. But "comparable to retinol in one small trial" is not "reverses skin aging." These are different claims.

Topical vs. Injectable: The Bioavailability Question

Most GHK-Cu products are topical serums. The compound has a molecular weight of approximately 340 daltons (as the free peptide) — below the roughly 500-dalton cutoff traditionally cited for significant transdermal penetration. So penetration is plausible.

"Plausible penetration" and "therapeutic concentrations at the dermis" are different things. Actual dermis concentration from topical application depends on formulation, carrier system, skin barrier integrity, and application method. Most topical GHK-Cu studies measure surface effects (wrinkle depth, photographic improvement) rather than direct tissue GHK-Cu concentration measurement, because measuring tissue drug concentrations requires biopsies that cosmetic trials rarely include.

Injectable GHK-Cu protocols — increasingly common in peptide biohacking circles — bypass the penetration question entirely but introduce different unknowns: systemic effects of the compound at concentrations higher than topical delivery, long-term effects of repeated administration, and the quality control issues endemic to gray-market peptide sourcing. The injectable human data is essentially nonexistent, and the wound-healing topical trials don't translate directly to injected systemic use.

What the Gene Expression Data Means (And Doesn't)

Pickart's work on GHK-Cu's effects on gene expression is frequently cited in marketing copy. The compound affects expression of thousands of genes, including genes relevant to DNA repair, antioxidant defense, and tissue remodeling. This is presented as evidence of profound anti-aging activity.

The more careful interpretation: a compound that modulates thousands of genes is doing something significant. What exactly that something is, whether it is beneficial or neutral for all affected pathways, and whether the in vitro and animal gene expression changes translate to meaningful phenotypic outcomes in humans at cosmetic doses, is not fully characterized. Broad transcriptional activity is not the same as proven efficacy for any specific outcome. It could mean the compound is doing a lot of useful things. It could mean the compound is doing a lot of things, some of which are useful. The research needed to distinguish these interpretations hasn't been done at scale.

Where GHK-Cu Sits in Honest Context

Compared to most peptides being marketed to consumers, GHK-Cu has a relatively strong evidence base. The wound-healing data is real. The mechanistic picture is well-developed. The topical safety profile over decades of use is reassuring. For topical cosmetic use at standard formulation concentrations, this is one of the more defensible active ingredients in peptide skincare.

The claims that exceed the evidence: that it "reverses aging" in the way pharmaceutical intervention would, that the gene expression data proves profound systemic rejuvenation, and that injectable protocols deliver the same benefit profile as the topical wound-healing trials. None of these are established.

The honest summary: GHK-Cu topical products are among the better-evidenced cosmetic peptide options available, with real but modest clinical support for skin improvement outcomes. Injectable GHK-Cu is a different compound in a different context with essentially no human clinical data. The marketing conflates them. The evidence does not.

Bottom Line

GHK-Cu is not snake oil. It's also not the fountain of youth. It's an interesting compound with real mechanisms, decent wound-healing evidence, and modest cosmetic trial data that doesn't fully support the most aggressive anti-aging claims. If you're evaluating an anti-aging product claim that features GHK-Cu, score the specific claim — not just the compound, but the particular outcome being promised. That's where the gap between "interesting ingredient" and "proven result" usually lives.

For a broader framework on how to evaluate any peptide claim before spending money on it, see our guide on how to evaluate peptide claims.